All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On September 4, 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for axicabtagene ciloleucel (axi-cel) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL) after two or more prior lines of systemic therapy.1
Axi-cel, an anti-CD19 autologous chimeric antigen receptor (CAR) T-cell product, is already approved for the treatment of adult patients with R/R large B-cell lymphoma (LBCL) after ≥ 2 lines of systemic therapy, and previously the FDA granted breakthrough therapy designation to axi-cel for R/R FL or MZL. In case of approval, axi-cel would be the first commercial CAR T-cell therapy approved for R/R FL or MZL.
The sBLA submission was based on data from the ongoing single-arm, multicenter, open-label, phase II ZUMA-5 trial (NCT03105336). Interim results of this study were reported at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Axi-cel showed high rates of durable responses and a manageable safety profile (read the full article on the ZUMA-5 study, here).
Axi-cel could represent a valid treatment option for patients with late line R/R FL and MZL who have exhausted other approved treatment options.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox